BPH and Inflammation: Pharmacological Effects of Permixon on Histological and Molecular Inflammatory Markers. Results of a Double Blind Pilot Clinical Assay

Navarrete, Remigio Vela; Cardoso, Juan Vicente García; Barat, A.; Manzarbeitia, Félix; Farré, Antonio López

doi:10.1016/s0302-2838(03)00368-3

Cited by 81 publications

(53 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the study by Vela Navarrete et al, SeR alone showed a reduction of the biological markers (TNFα and IL-1β): however, the histological findings resulted in a reduction only in the number of lymphocytes B (CD20) (23).…”

Section: Discussionmentioning

confidence: 91%

“…Tumor necrosis factor-α and IL-1b were dramatically lower in the Serenoa repens-treated group; both biological markers have been used as indicators of prostatic inflammation in cases of chronic prostatitis (23).…”

Section: Discussionmentioning

confidence: 98%

“…Since the infiltration of inflammatory cells appears to have a role in BPH, inhibition of the production of chemotactic leukotrienes and other 5 lypoxygenase metabolites by Serenoa repens could be useful in BPH treatment (23).…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Effects of Serenoa Repens, Selenium and Lycopene (Profluss®) on chronic inflammation associated with Benign Prostatic Hyperplasia: results of “FLOG” (Flogosis and Profluss in Prostatic and Genital Disease), a multicentre Italian study

et al. 2013

View full text Add to dashboard Cite

Objective: To evaluate the efficacy of Profluss® on prostatic chronic inflammation (PCI). Materials and Methods:We prospectively enrolled 168 subjects affected by LUTS due to bladder outlet obstruction submitted to 12 cores prostatic biopsy for suspected prostate cancer + 2 cores collected for PCI valuation. First group consisted of 108 subjects, with histological diagnosis of PCI associated with BPH and high grade PIN and/or ASAP, randomly assigned to 1:1 ratio to daily Profluss® (group I) for 6 months or to control group (group Ic). Second group consisted of 60 subjects, with histological diagnosis of BPH, randomly assigned to 1:1 ratio to daily Profluss® + α-blockers treatment (group II) for 3 months or to control group (group IIc). After 6 months first group underwent 24 cores prostatic re-biopsy + 2 cores for PCI while after 3 months second group underwent two-cores prostatic for PCI. Specimens were evaluated for changes in inflammation parameters and for density of T-cells (CD3, CD8), B-cells (CD20) and macrophages (CD68). Results: At follow-up there were statistical significant reductions of extension and grading of flogosis, mean values of CD20, CD3, CD68 and mean PSA value in group I compared to Ic, while extension and grading of flogosis in group II were inferior to IIc but not statistical significant. A statistically significant reduction in the density of CD20, CD3, CD68, CD8 was demonstrated in group II in respect to control IIc. Conclusions: Serenoa repens+Selenium+Lycopene may have an anti-inflammatory activity that could be of interest in the treatment of PCI in BPH and/or PIN/ASAP patients.

show abstract

Section: Discussionmentioning

confidence: 91%

Section: Discussionmentioning

confidence: 98%

See 1 more Smart Citation

Effects of Serenoa Repens, Selenium and Lycopene (Profluss®) on chronic inflammation associated with Benign Prostatic Hyperplasia: results of “FLOG” (Flogosis and Profluss in Prostatic and Genital Disease), a multicentre Italian study

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Prostatik enflamasyona yönelik tedavinin BPH'nın önlenmesi veya buna bağlı AÜS yakınmalarının giderilmesi açısından önemli olabileceği düşünülerek farklı türde anti-enflamatuvar ajanlar in vitro ve in vivo ortamda kullanılarak farklı klinik çalışmalar yayınlanmıştır (14,15,35). Genellikle COX-2 ve antiapoptotik bcl-2 yolağının prostatik enflamasyonda rolü olabileceğini gösteren çalışmalardan sonra, bu mekanizmalar üzerinden etki edebilecek tedavilerin denendiği sınırlı sayıda çalışma yayınlanmıştır (14,15).…”

Section: Anti-enflamatuvar Tedavi Ve Benign Prostat Hiperplazisiunclassified

“…Vela ve ark. 'nın (35) yapmış olduğu plasebo kontrollü bir çalışmada, prostatektomi öncesi 3 haftalık serenoa repens tedavisinin IL-1β ve TNFα gibi enflamasyonda önemli rol oynayan proenflamatuvar faktörleri ve B lenfosit miktarını azalttığı saptanmıştır. D vitamini reseptör agonistlerinin anti-enflamatuvar özellikleri bilinmektedir (39).…”

Section: Anti-enflamatuvar Tedavi Ve Benign Prostat Hiperplazisiunclassified

The Role of Enflammation as an Etiopathogenetic Mechanism and Treatment Target in Benign Prostatic Hyperplasia

Tekın¹,

Yüksel²

2015

uob

View full text Add to dashboard Cite

Benign prostat hiperplazisinin (BPH) etiyopatogenezi henüz tam olarak aydınlatılmamış olmakla birlikte, güncel literatür bilgileri prostatik enflamasyonun etiyolojide önemli olabileceğini ve tedavi hedefi olarak bir potansiyel olabileceğini işaret etmektedir. Sadece prostatik enflamasyonun varlığı değil, aynı zamanda bunun derecesi ve şiddeti, Uluslararası Prostat Semptom Skoru ile yakın ilişkili olup, BPH progresyonunu (semptom artışı, akut üriner retansiyon, cerrahi gerekliliği) belirleyici özelliğe sahiptir. Enflamasyonun hangi mekanizma ile BPH oluşumuna neden olduğu tam olarak aydınlatılmamıştır. Bununla birlikte, yaşlanmaya bağlı immünite zayıflaması ve ortaya çıkan hormonal değişikliklerin rolü olabilir. Oksidatif stres, androjen bağımlı genler ve tümör growth faktör-β1 kaskad genlerinin artışı, prostatik antijenleri görmemeyi sağlayan baskılayıcı hücrelerin azalması, IL-6, IL-8, IL-15 gibi proenflamatuvar sitokinler ile siklooksigenaz-2 ekspresyonu etkisiyle yıkıcı enflamatuvar hücrelerin infiltrasyonu sonucu gelişen zincirleme olaylar da BPH oluşumuna katkı sağlayabilir. Kanıta dayalı veriler nonsteroid anti-enflamatuvar ilaç kullanımının enflamasyonu baskılayıcı mekanizma üzerinden prostat büyümesini, alt üriner sistem yakınmalarının progresyonunu, idrar akım hızında azalmayı ve prostatspesifik antijen yükselmesini engelleyebileceğini veya geciktirebileceğini göstermektedir. Bunun yanında, D vitamini agonistleri, serenoa repens ve fosfodiesteraz-5 inhibitörlerinin BPH tedavisindeki etkinliklerinin bir kısmından enflamasyonu baskılamaları sorumlu olabilir. Sonuç olarak prostatik enflamasyon BPH patogenezinde ve progresyonunda önemli bir role sahip gibi görünmektedir. Anti-enflamatuvar etkili ilaçların yakın gelecekte BPH'nın medikal tedavisinde daha fazla yer alması beklenmelidir. Anahtar Kelimeler: Prostatit, benign prostat hiperplazisi, enflamasyon, anti-enflamatuvar tedavi Despite the etiopathogenesis of benign prostatic hyperplasia (BPH) has not yet been elucidated exactly, current data indicate that the prostatic inflammation may be important in the etiology and it may be a potential for a treatment target. Not only the presence of prostatic inflammation, but also its grade and severity are related to International Prostate Symptom Score and have a capability to predict the progression of BPH (increase in symptom severity, acute urinary retention, and the need for surgery). Although the mechanism of inflammation on the development BPH has not been fully understood, it is probably associated with the weakening of the immune system and hormonal alterations with aging. Subsequent cascade of events including oxidative stress, upregulation of androgen-responsive genes and transforming growth factor β1 cascade genes, decrease of a population of suppressor cells that actively suppresses the recognition of prostatic antigens and an increase in proinflammatory cytokines such as IL-6, IL-8, IL-15 and cyclooxygenase-2 expression may induce the development of BPH. Evidence-based data revealed that non-steroid...

show abstract

Serenoa repensfor benign prostatic hyperplasia

Tacklind¹,

MacDonald²,

Rutks³

et al. 2009

Cochrane Database of Systematic Reviews

101

View full text Add to dashboard Cite

Background-Benign prostatic hyperplasia (BPH), a nonmalignant enlargement of the prostate, can lead to obstructive and irritative lower urinary tract symptoms (LUTS). The pharmacologic use of plants and herbs (phytotherapy) for the treatment of LUTS associated with BPH is common. The extract of the berry of the American saw palmetto, or dwarf palm plant, Serenoa repens (also known by its botanical name of Sabal serrulatum), is one of several phytotherapeutic agents available for the treatment of BPH.Objectives-This systematic review aimed to assess the effects of Serenoa repens in the treatment of LUTS consistent with BPH.Search strategy-Trials were searched in computerized general and specialized databases (MEDLINE, EMBASE, and The Cochrane Library), by checking bibliographies, and by handsearching the relevant literature.Selection criteria-Trials were eligible if they (1) randomized men with symptomatic BPH to receive preparations of Serenoa repens (alone or in combination) for at least four weeks in comparison with placebo or other interventions, and (2) included clinical outcomes such as urologic symptom scales, symptoms, and urodynamic measurements. Eligibility was assessed by at least two independent observers. Data collection and analysis-Information on patients, interventions, and outcomes was extracted by at least two independent reviewers using a standard form. The main outcome measure for comparing the effectiveness of Serenoa repens with placebo or other interventions was the change in urologic symptom-scale scores. Secondary outcomes included changes in nocturia and urodynamic measures. The main outcome measure for side effects or adverse events was the number of men reporting side effects.Main results-In this update 9 new trials involving 2053 additional men (a 64.8% increase) have been included. For the main comparison -Serenoa repens versus placebo -3 trials were added with 419 subjects and 3 endpoints (IPSS, peak urine flow, prostate size). Overall, 5222 subjects from 30 randomized trials lasting from 4 to 60 weeks were assessed. Twenty-six trials were double blinded and treatment allocation concealment was adequate in eighteen studies.

show abstract

BPH and Inflammation: Pharmacological Effects of Permixon on Histological and Molecular Inflammatory Markers. Results of a Double Blind Pilot Clinical Assay

Cited by 81 publications

References 18 publications

Effects of Serenoa Repens, Selenium and Lycopene (Profluss®) on chronic inflammation associated with Benign Prostatic Hyperplasia: results of “FLOG” (Flogosis and Profluss in Prostatic and Genital Disease), a multicentre Italian study

Effects of Serenoa Repens, Selenium and Lycopene (Profluss®) on chronic inflammation associated with Benign Prostatic Hyperplasia: results of “FLOG” (Flogosis and Profluss in Prostatic and Genital Disease), a multicentre Italian study

The Role of Enflammation as an Etiopathogenetic Mechanism and Treatment Target in Benign Prostatic Hyperplasia

Serenoa repensfor benign prostatic hyperplasia

Contact Info

Product

Resources

About